Please use this identifier to cite or link to this item:
|Title:||A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.|
|Authors:||Lau, David K;Andrews, Miles C;Turner, Natalie;Azad, Arun A;Davis, Ian D;Cebon, Jonathan S|
|Affiliation:||aLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australia.|
|Citation:||Melanoma Research; 24(2): 144-9|
|Abstract:||We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)≥2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16%) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.|
|Internal ID Number:||24463460|
Aged, 80 and over
Antineoplastic Agents.adverse effects.therapeutic use
Imidazoles.adverse effects.therapeutic use
Oximes.adverse effects.therapeutic use
Skin Neoplasms.drug therapy.pathology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.